The cost-effectiveness of drug-eluting stents: A systematic review

CMAJ. Canadian Medical Association Journal

Volumn 176, Issue 2, 2007, Pages 199-205

  Ligthart, Suzanne ^a,b   Vlemmix, Floortje ^a,b   Dendukuri, Nandini ^b,c   Brophy, James M ^b,c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 33846534132     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.061020     Document Type: Review

References (41)

1. Ong AT, Serruys PW. Technology insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med 2005;2:647-58.
2. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
3. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
5. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the Sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
6. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
7. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-related stents. Lancet 2004;364:583-91.
8. Brophy JM. The dollars and sense of drug-eluting stents. CMAJ 2005;172:361-2.
9. Ward MR. Cost-benefit of drug-eluting stents; time for a reality check. Heart Lung Circ 2005;14:74-7.
10. Feder BJ. J. & J. deal for stent maker clouded by patent disputes. NY Times 2006 Nov 18. Available http://query.nytimes.com/gst/fullpage. html?sec=health&res =9C00E7DF153EF93BA25752C1A9609C8B63 (accessed 2006 Dec 5).
11. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs Paclitaxel-eluting stents in patients with coronary artery disease. JAMA 2005;294:819-25.
12. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000;132:964-72.
13. Chiou C, Hay J, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41:32-44.
14. Spiegel BMR, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology 2004;127:403-11.
15. Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees [Wadsworth statistics/probability series]. Boca Raton (FL): Chapman & Hall/CRC; 1984.
16. Crichton NJ, Hinde JP, Marchini J. Models for diagnosing chest pain: Is CART helpful? Stat Med 1997;16(7):717-27.
17. Greenberg D, Cohen DJ. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. Z Kardiol 2002;91:137-43.
18. Galanaud JP, Delavennat J, Durand-Zaleski I. A break-even price calculation for the use of sirolimus-eluting stents in angioplasty. Clin Ther 2003;25:1007-16.
19. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-8.
20. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-14.
21. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1-242.
22. Tarricone R, Marchetti M, Lamotte M, et al. What reimbursement for coronary revascularization with drug-eluting stents? Eur J Health Econ 2004;5:309-16.
23. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-33.
24. Lord SJ, Howard K, Allen F, et al. A systematic review and ecomomic analysis of drug-eluting coronary stents available in Australia. Med J Aust 2005;183:464-71.
25. Bagust A, Grayson AD, Palmer ND, et al. Cost-effectiveness of drug-eluting coronary artery stenting in a UK setting: cost-utility study. Heart 2006;92:68-74.
26. Van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12.
27. Shrive FM, Manns BJ, Galbraith PD, et al. APPROACH Investigators. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172:345-51.
28. Kaiser C, Brunner-La Rocca P, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effectivitats Trial (BASKET). Lancer 2005;366:921-9.
29. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 2006;48:253-61.
30. Ekman M, Sjogren I, James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J. 2006;40:17-24.
31. Ikeda S, Kobayashi M: Economic evaluation of drug-eluting stents in Japan. Keio J Med 2006;55:15-22.
32. Ruffy R, Kaden RJ. Projected health and economic benefits of the use of sirolimus-eluting coronary stents. Adv stud med 2003; 3(6D): 602-11.
33. Mittmann N, Brown A, Seung SJ, et al. Drug eluting stents: an economic evaluation. (Technology overview no. 15). Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005. Available: www.cadth.ca/media/ pdf/372 _drug_eluting_stents_ov_e.pdf (accessed 2006 Nov 8).
34. Bowen J, Hopkins R, He Y, et al. Systematic review and cost-effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario. Interim Report for the Ontario Ministry of Health and Long-term Care. Report No.: HTA002-0512. Hamilton (ON): Program for Assessment of Technology in Health, McMaster University; 2005. p.170. Available: www .path-hta.ca/DESreport.pdf (accessed 2006 Nov 8).
35. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
36. Biondi-Zoccai GGL, Lotrionte M, Abbate A, et al. Compliance with QUORUM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006;332:202-9.
37. Stelfox HT, Chua G, O'Rourke K, et al. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.
38. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699-703.
39. Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004;329:972-5.
40. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
41. Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005;149:434-43.